Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension

NCT07820085 is registered in ClinicalTrials.gov with Portal Therapeutics, Inc. as lead sponsor.

NCT NCT07820085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07820085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension
Lead sponsor
Portal Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
225 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epp2, erythropoietic protoporphyria (epp), x-linked protoporphyria (xlp)